2024 Catch-Up Vaccination Schedule: 4 Months-18 Years

*The tables provide catch‑up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age. Always use this table in conjunction with the child and adolescent immunization schedules (“Vaccination Schedule: 0−18 Years of Age”) and their respective footnotes.

 1. Hepatitis B (HepB) vaccine. (Minimum age: birth)

• Unvaccinated persons should complete a 3-dose series at 0, 1–2, 6mos.

• A 2‑dose series (doses separated by at least 4mos) of adult formulation Recombivax HB may be given to children aged 11−15yrs.

• A 2-dose series at least 4wks apart of Heplisav-B, a 3-dose series at 0, 1, 6mos of PreHevbrio, or a 3- or 4-dose series of the combined HepA and HepB vaccine (Twinrix) may be given to adolescents aged ≥18yrs.

 2. Rotavirus (RV) vaccines (Minimum age: 6wks for both RV1 [Rotarix] and RV5 [RotaTeq])

• Vaccination series should not be initiated on or after age 15wks, 0 days. The maximum age for final dose is 8mos, 0 days.

• Administer a 2-dose series (Rotarix) or a 3-dose series (Rotateq). If any dose in the series is either Rotateq or unknown, default to a 3-dose series.

 3. Diphtheria, tetanus, and acellular pertussis (DTaP) vaccine. (Minimum age: 6wks. Exception: DTaP‑IPV [Kinrix, Quadracel]: 4yrs)

• The 5th dose of DTaP vaccine is not needed if 4th dose was given at age ≥4yrs and ≥6mos after 3rd dose.

 4. Haemophilus influenzae type b (Hib) conjugate vaccine. (Minimum age: 6wks for PRP‑T [ActHIB, Hiberix], PRP‑OMP [PedvaxHIB], DTaP‑IPV/Hib [Pentacel], DTaP-IPV-Hib-HepB [Vaxelis])

• If the 1st dose was given at age 7−11mos, give the 2nd dose at least 4wks later and a 3rd (and final) dose at age 12−15mos or 8wks after 2nd dose, whichever is later.

• If 1st dose was given at ages 12−14mos, give 2nd (final) dose at least 8wks after dose 1.

• If 1st dose is given before 1st birthday and 2nd dose is given <15mos of age, a 3rd (and final) dose should be given at least 8wks after 2nd dose.

• If 2 doses of PedvaxHIB were given before 1st birthday, the 3rd (and final) dose should be given at age 12−59mos and at least 8wks after the 2nd dose.

• If 1 dose was given at age ≥15mos, no further doses needed.

• For unvaccinated children aged 15–59mos, give only 1 dose.

• Unvaccinated children age ≥60mos who are not considered high risk do not require catch-up vaccination.

• Vaxelis can be used for catch-up vaccination in children age <5yrs.

 5. Pneumococcal vaccines. (Minimum age: 6wks for PCV15 and PCV20, 2yrs for PPSV23)

• Give 1 dose of PCV15 or PCV20 to healthy children ages 2–4yrs with any incomplete PCV series.

• PCV20 is not indicated in healthy children if previously received 4 doses of PCV13 or PCV15 or another complete PCV series.

 6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6wks)

• In the first 6mos of life, minimum age and minimum intervals are only recommended if the person is at risk for imminent exposure to circulating poliovirus (eg, travel to a polio-endemic region or during an outbreak).

• If both trivalent OPV (tOPV) and IPV were given as part of a series, a total of 4 doses should be given to complete the series. Doses should be at least 4wks apart, with the final dose given on or after the 4th birthday and at least 6mos after the previous dose. If only OPV were given, and all doses given before 4yrs of age, 1 dose of IPV should be given at age ≥4yrs, at least 6mos after last OPV dose.

• Only tOPV counts toward the US vaccination requirements. Doses of OPV given before 4/1/2016 should be counted (unless noted as given during a campaign). Doses of OPV given on or after 4/1/2016 should not be counted.

• Unvaccinated or incompletely vaccinated adolescents age 18yrs should receive remaining IPV doses to complete a 3-dose primary series. Those who completed the primary series and remains at risk may receive one lifetime IPV booster.

 7. Influenza vaccines. (Minimum age: 6mos for inactivated influenza vaccine [IIV], 2yrs for live attenuated influenza vaccine [LAIV4], 18yrs for recombinant influenza vaccine [RIV4])

• Use any age and health status-appropriate influenza vaccine annually.

• See “VACCINATION SCHEDULE: 0−18 YEARS OF AGE” for further guidance.

 8. Measles, mumps, and rubella (MMR) vaccine. (Minimum age: 12mos for routine vaccination)

• Unvaccinated persons should complete a 2-dose series at least 4wks apart.

• Maximum age for MMRV vaccine: 12yrs.

• Minimum interval between MMRV doses: 3mos

 9. Varicella (VAR) vaccine. (Minimum age: 12mos)

• Ensure that all persons aged 7−18yrs without evidence of immunity have 2 doses of varicella vaccine. For children aged 7−12yrs, the recommended interval between doses is 3mos (if the 2nd dose was given at least 4wks after the 1st dose, it can be accepted as valid); for persons aged ≥13yrs, the routine interval between doses is 4–8wks.

• Maximum age for MMRV vaccine: 12yrs.

10. Hepatitis A vaccine (HepA). (Minimum age: 12mos)

• Unvaccinated children through 18yrs should complete 2 doses ≥6mos apart.

• Children who previously received 1 dose at age ≥12mos should receive 2nd dose ≥6mos after 1st dose.

• Adolescents aged ≥18yrs may receive a 3- or 4-dose series of the combined HepA and HepB vaccine (Twinrix).

11. Meningococcal vaccines. (Minimum age: 2mos for MenACWY-CRM [Menveo], 2yrs for MenACWY-TT [MenQuadfi], 10yrs for serogroup B meningococcal [MenB] vaccines: MenB-4C [Bexsero] and MenB-FHbp [Trumenba], 10yrs for MenACWY-TT/MenB-FHbp [Penbraya])

• MenACWY vaccines:

− Age 13-15yrs: give 1 dose and a booster at age 16-18yrs (≥8wks between doses).

− Age 16-18yrs: give 1 dose

− If not previously vaccinated at 16yrs, give 1 dose to 1st-year college students living in residential housing or military recruits.

• MenB vaccines:

− a 2-dose series may be given based on shared clinical decision-making to persons 16−23yrs (16−18 preferred) who are not at increased risk.

− Bexsero and Trumenba are not interchangeable; use the same product for all doses in a series.

• MenACWY and MenB vaccines may be given simultaneously but at different anatomic sites, if feasible.

• Children age ≥10yrs may receive 1 dose of Penbraya as an alternative to separate administration of MenACWY and MenB when both vaccines would be given on the same clinic day.

− Children not at increased risk: if Penbraya is used for 1st dose of MenB, Trumenba should be given for 2nd dose.

− Children at increased risk: Penbraya may be used for additional MenACWY and MenB doses (including booster). The interval between Penbraya doses is ≥6mos.

12. Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine. (Minimum age: 11yrs for routine vaccination, 7yrs for catch-up)

• Persons 13−18yrs who have not received Tdap vaccine should receive 1 dose of Tdap (adolescent booster).

• Persons 7−18yrs not fully immunized with DTaP should receive 1 dose of Tdap as part of the catch-up series (preferably 1st dose). Give Td or Tdap if more doses are needed.

• Children age 7−9yrs who receive Tdap should receive the adolescent Tdap booster dose at age 11–12yrs. Children age 10yrs who receive Tdap do not need the adolescent Tdap booster dose at age 11–12yrs.

• Inadvertent doses of DTaP vaccine:

− If administered inadvertently at age 7–9yrs, DTaP may count as part of the catch‑up series. The adolescent Tdap booster should be given at age 11–12yrs.

− If administered inadvertently at age 10−18yrs, the dose should be counted as the adolescent Tdap booster.

13. Human papillomavirus (HPV) vaccines. (Minimum age: 9yrs for 9vHPV [Gardasil 9])

• Give HPV vaccine to all adolescents age 11–12yrs (can start at 9yrs) and through age 18yrs if not adequately vaccinated.

• Give 2 doses at 0, 6−12mos if initiating vaccination at age 9−14yrs. Minimum interval between doses is 5mos; repeat dose if given too soon.

• Give 3 doses at 0, 1−2, 6mos if initiating vaccination at age ≥15yrs. Minimum intervals are 4wks between 1st and 2nd dose, 12wks between 2nd and 3rd dose; and 5mos between 1st and 3rd dose; repeat dose if given too soon.

• Series does not need to be restarted if vaccination schedule is interrupted.

• No additional doses needed if valid vaccination series completed with any HPV vaccine.

14. Dengue vaccine (Minimum age: 9yrs for DEN4CYD [Dengvaxia])

• Give 3 doses at 0, 6, 12mos in persons age 9−16yrs who live in dengue endemic areas and have laboratory-confirmed previous dengue infection

• Children traveling to or visiting dengue endemic areas should not be vaccinated.

15. Covid-19 vaccines (Minimum age: 6mos for Moderna and Pfizer-BioNTech vaccines; 12yrs for Novavax vaccine)

• ACIP recommends use of COVID-19 vaccines for everyone ages ≥6mos.

• Unvaccinated children and those previously vaccinated with any Original monovalent or bivalent COVID-19 vaccine (Janssen, Moderna, Novavax, Pfizer-BioNTech) should receive age-appropriate doses of the updated 2023-2024 formulation (no preferential recommendation for the use of any one vaccine over another).

• The Novavax vaccine remains authorized for use as a 2-dose primary series in children age ≥12yrs.

• The Original monovalent and bivalent (Original and Omicron BA.4/BA.5) formulations should no longer be used for vaccination. The Janssen vaccine is no longer available in the US.

• For a list of currently available COVID-19 vaccines and other recommendations for COVID-19 vaccination including dosing for immunocompromised adults, see https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.

16. Respiratory syncytial virus (RSV vaccine, RSV-mAb). (Minimum age: birth for nirsevimab [Beyfortus])

• Either maternal RSV vaccination with Abrysvo or infant immunization with nirsevimab is recommended to prevent RSV lower respiratory tract infection in infants.

• Infants: give 1 dose of nirsevimab; timing of administration is dependent on birth month (RSV seasonality) and mother’s RSV vaccination status. Nirsevimab can be given to children who are eligible to receive palivizumab. If previously received nirsevimab, palivizumab should not be given for the same RSV season.

• Pregnant persons: give 1 dose of RSV vaccine Abrysvo at 32wks 0 days through 36wks 6 days gestation from September through January, regardless of previous RSV infection. There is currently no recommendation for RSV vaccination in subsequent pregnancies.

• See “VACCINATION SCHEDULE: 0−18 YEARS OF AGE” for further guidance

17. Mpox vaccine. (Minimum age: 18yrs for Jynneos)

• Give a 2-dose series, 28 days apart, to persons age 18yrs and at risk for mpox infection

NOTE: Refer to the ACIP 2024 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger footnotes for vaccinations of persons with high risk conditions or other special situations.

• The 20-valent pneumococcal conjugate vaccine (PCV20), Mpox vaccine (Jynneos), RSV monoclonal antibody (nirsevimab), RSV vaccine (Abrysvo), and MenACWY-TT/MenB-FHbp vaccine (Penbraya) has been added to the vaccination schedule.

• PCV13 has been removed from the schedule and the pneumococcal footnote has been updated with the new recommendations for PCV15, PCV20, and PPSV23.

• The polio footnote has been revised to include updated recommendations for adolescents age 18yrs.

• The meningococcal vaccines footnote has been updated to remove Menactra and include recommendation for the use of the new meningococcal A, B, C, W, Y vaccine (Penbraya).

• The Tdap footnote has been revised to clarify the adolescent booster dose at age 11-12yrs.

• The COVID-19 footnote has been revised to include the updated Covid-19 vaccines 2023-2024 formulation.

• An RSV immunization footnote has been added to provide guidance on the use of nirsevimab in infants and RSV vaccine (Abrysvo) during pregnancy.

• An Mpox vaccine footnote has been added to provide guidance for the use of Jynneos.

For information on individual vaccines see product monographs, contact the manufacturer, or call the National Immunization Hotline at (800) 232-4636. Advisory Committee on Immunization Practices (ACIP). Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind, United States, 2024. Accessed January 23, 2024. https://www.cdc.gov/vaccines/schedules/hcp/imz/catchup.html.

Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. Updated January 18, 2024. Accessed January 24, 2024. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.

(Rev. 2/2024)